# Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

> **NCT03314636** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 53 (actual)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DEVICE:** PET-CT
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03314636
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-16
- **Primary completion:** 2021-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314636, "Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03314636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*